Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Common Equity for 3 consecutive years, with $110.0 million as the latest value for Q4 2025.
- On a quarterly basis, Common Equity fell 41.08% to $110.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $110.0 million, a 41.08% decrease, with the full-year FY2025 number at $110.0 million, down 41.08% from a year prior.
- Common Equity was $110.0 million for Q4 2025 at Artiva Biotherapeutics, down from $129.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $201.0 million in Q3 2024 to a low of -$191.1 million in Q2 2024.
- A 3-year average of $9.2 million and a median of $110.0 million in 2025 define the central range for Common Equity.
- Peak YoY movement for Common Equity: skyrocketed 232.71% in 2024, then plummeted 41.08% in 2025.
- Artiva Biotherapeutics' Common Equity stood at -$162.0 million in 2023, then skyrocketed by 215.2% to $186.6 million in 2024, then tumbled by 41.08% to $110.0 million in 2025.
- Per Business Quant, the three most recent readings for ARTV's Common Equity are $110.0 million (Q4 2025), $129.2 million (Q3 2025), and $149.0 million (Q2 2025).